Bacteria may assist the immune system response against cancer

Bacteria may enhance the body’s ability to fight melanoma
Associate Professor Alex McLellan.

(Medical Xpress)—Recent research from the University of Otago shows that bacteria may assist the body's immune system response against cancer cells and help fight tumours like melanoma.

The research published in the official journal of the American Association of Immunologists, the Journal of Immunology, demonstrates that bacteria stimulate a type of immune response that results in more effective killer cell attacks against cancer.

Associate Professor Alex McLellan from the Department of Microbiology and Immunology says the new results are very encouraging and will prompt further investigation using human cells and .

"By using bacteria we can excite an immune response against cancer and our results show that natural killer cells are very important in this enhanced response," Dr McLellan explains.

"What we've discovered is that these natural killer cells are stimulated by bacteria to enhance the potency of the immune response to the tumour. Interestingly, natural killer cells don't seem to make the vaccine any stronger, but rather enhance the visibility of the tumour to the immune response induced by vaccination."

Associate Professor McLellan says that this pathway further enhances the body's ability to attack by boosting tumour-specific T cells. The cells seem to be releasing growth factors which make other immune cell types better able to destroy the cancer.

Vaccination predominantly stimulates an 'adaptive' . Since were initially classed as members of the innate, or primitive, arm of the immune system, they were thought to play no part in protection afforded by vaccination. But this research shows important links between the innate and adaptive response of the body in anti-tumour immunity, says Dr McLellan.

An immunological approach to cancer harks back to over 120 years ago to Coley's toxins, says Dr McLellan. American surgeon William Coley discovered in the 1890s that when a patient is inoculated or even infected with this can have a significant effect or even destroy the cancer. This approach was not seriously pursued after the development of chemotherapy and radiation.

Now this area of research is again being reactivated as another possible tool in the fight against cancer.

Associate Professor McLellan says the next step is to test these very positive findings using , and then extend it to cancer patients through collaborators in Germany.

add to favorites email to friend print save as pdf

Related Stories

Discovery brings cancer immune therapies a step closer

Feb 05, 2014

(Medical Xpress)—The development of new therapies to enhance the body's immune response to cancer is much closer after University of Otago scientists identified a pathway that alters the immune response ...

Recommended for you

Endogenous hormones improve breast cancer risk models

3 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

4 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dedereu
not rated yet Mar 27, 2014
Incredible but true : a century lost, with no better cure, than 100 years ago with Coley :
" back to over 120 years ago to Coley's toxins,... American surgeon William Coley discovered in the 1890s that when a patient is inoculated or even infected with bacteria this can have a significant effect or even destroy the cancer. This approach was not seriously pursued after the development of chemotherapy and radiation.""
Read :
http://www.nature...S4a.html
"Half of Coley's sarcoma patients lived for ten years, compared with 38% of those treated with modern therapy. Coley also improved the ten-year survival rates for patients with kidney and ovarian cancers. "What Coley did for his [sarcoma] patients back then was better than what we're doing for these same patients today," says Charlie Starnes"